HemaQuest Pharmaceuticals Obtains $13,000,000 Series B Financing

  • Feed Type
  • Date
    3/12/2012
  • Company Name
    HemaQuest Pharmaceuticals
  • Mailing Address
    11995 El Camino Real San Diego, CA 92130
  • Company Description
    HemaQuest is a company developing proprietary small molecule therapeutics to treat serious blood disorders.
  • Website
    http://www.hemaquest.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $13,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to fund a randomized, double-blind, placebo-controlled Phase 2b clinical study evaluating lead product candidate HQK-1001 in patients with sickle cell disease. The Company believes this financing, combined with existing cash balances, will be sufficient to allow completion of the Phase 2b trial and to fund operations through early 2014.
  • M&A Terms
  • Venture Investor
    Aberdare Ventures
  • Venture Investor
    De Novo Ventures
  • Venture Investor
    Forward Ventures
  • Venture Investor
    Latterell Venture Partners
  • Venture Investor
    Lilly Ventures

By posting a comment, you agree to our terms and conditions.